Following the clinical success from the combined use of BRAF and MEK inhibitors in BRAFV600E-mutant melanoma [52,85], the BRAF and MEK inhibitor combination was systematically evaluated in the context of BRAFV600E-mutant NSCLC. Here, MAP2K7 is linked to melanoma.